Phaseline

Targets › PTDSS1

PTDSS1 (Phosphatidylserine synthase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jan 2027.

Catalyzes a base-exchange reaction in which the polar head group of phosphatidylethanolamine (PE) or phosphatidylcholine (PC) is replaced by L-serine. Catalyzes mainly the conversion of phosphatidylcholine. (UniProt, P48651)

Open in Phaseline: the race on PTDSS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Maryland, BaltimoreBavituximab
Anti-phosphatidylserine monoclonal antibody that binds to phosphatidylserine after binding
PTDSS1Phase 2Squamous Cell CarcinomaJan 2027

Conditions

Squamous Cell Carcinoma (1)

Modalities

antibody (1)

Companies

University of Maryland, Baltimore (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.